Skip to main content
Fig. 1 | Acta Neuropathologica Communications

Fig. 1

From: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

Fig. 1

Flowchart of patient selection. For Cohort 1, 758 out of 881 Grade II-IV cases collected met the eligibility criteria and were analyzed for the prognostic impact of IDH and TERT status in adult diffuse gliomas. From Cohort 1, 260 GBM patients concurrently treated with TMZ and RT were further selected (Cohort 1 GBM). For Cohort 2, 193 IDH wild-type GBM cases treated with TMZ plus RT were selected (Cohort 2 GBM). Cohort 1 GBM and Cohort 2 GBM were analyzed for the influences of TERT and MGMT status on survival. GBM, glioblastoma; NF, neurofibromatosis; RT, radiation therapy; TMZ, temozolomide

Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us